| 42240-2 |
CHD7 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
CHD7 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
METHOD: THE ENTIRE KNOWN CODING SEQUENCE OF THE CHD7 GENE (EXON 1 THROUGH 40) AND THE INTRON/EXON BOUNDARIES WERE PCR-AMPLIFIED FROM GENOMIC DNA OF THE SUBMITTED SPECIMEN AND SUBJECTED TO BI-DIRECTIONAL SEQUENCE ANALYSIS. RESULT: Negative NO DISEASE-ASSOCIATED MUTATION WAS IDENTIFIED IN THE CHD7 GENE. A HETEROZYGOUS POSITION (PRO2121PRO CCG/CCA) OF NO KNOWN CLINICAL SIGNIFICANCE WAS OBSERVED. INTERPRETATION: IN ONE STUDY OF 17 PATIENTS WITH CHARGE SYNDROME WHO DID NOT HAVE MICRODELETIONS, 10 INDIVIDUALS WERE IDENTIFIED AS HAVING HETEROZYGOUS MUTATIONS IN THE CHD7 GENE. BASED ON THIS SMALL SAMPLE SIZE, APPROXIMATELY 59% OF INDIVIDUALS WITH CHARGE SYNDROME WITHOUT AN IDENTIFIABLE LARGE DELETION WILL HAVE A MUTATION IN THE CHD7 GENE. THE HETEROZYGOUS CHANGE IN CODON PRO2121 OF THE SUBMITTED SAMPLE IS SILENT AND NOT EXPECTED TO BE ASSOCIATED WITH THE PRODUCTION OF AN Abnormal PROTEIN. THE PRESENCE OF HETEROZYGOSITY IN THIS PATIENT RULES OUT A COMPLETE GENE DELETION AND DEMONSTRATES THAT BOTH CHD7 ALLELES ARE PRESENT AT THIS POSITION OF THE GENE. |
|
|
|
|
|
MOLPATH.MUT |
|
42240-2 |
|
Molgen |
|
|
Both |
|
|
|
0 |
CHD7 gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; chromodomain helicase DNA binding protein 7; Chromodomain helicase DNA binding protein 7 gene; CRG; Document; Finding; Findings; FLJ20357; FLJ20361; Genetics; Heredity; Heritable; HH5; Inherited; IS3; KAL5; KIAA1416; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.16 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 42241-0 |
Cocaine+Benzoylecgonine |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Cocaine+Benzoylecgonine [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
42241-0 |
|
Screen |
|
|
Both |
|
|
|
0 |
Cocaine+BZE Ur Ql Scn |
|
|
|
N |
|
Addiction; BEC; BEG; Benz; Benzoylec; Benzoylmethylecgonine; BZE; Cocaine degradation production; Cocaine metabolite; Cocaine+BZE; Coke; Crack; Crack metabolite; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Ecgonine methyl ester benzoate; Illicit; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; Snow; UA; UR; Urn |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42242-8 |
Ethanol |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Ethanol [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
42242-8 |
|
Screen |
|
|
Both |
|
|
|
0 |
Ethanol Ur Ql Scn |
|
|
|
N |
|
Alc; Alcohol; DRUG/TOXICOLOGY; Drugs; Ethyl alcohol; EtOH; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42243-6 |
Hemoglobin |
MCnc |
Bld |
Pt |
Qn |
HPLC |
|
DEPRECATED |
Deprecated Hemoglobin [Mass/volume] in Blood |
|
DEL |
DefinitionDescription |
|
|
g/dL |
|
|
|
|
|
|
HEM/BC |
|
42243-6 |
|
HPLC |
|
|
Both |
|
|
|
0 |
Deprecated Hgb Bld HPLC-mCnc |
|
|
|
N |
|
Blood; Haemoglobin; Hb; HEMATOLOGY/CELL COUNTS; Hgb; High performance liquid chromatography; High pressure liquid chromatography; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 42244-4 |
Hemoglobin A/Hemoglobin.total |
MFr |
Bld |
Pt |
Qn |
HPLC |
|
ACTIVE |
Hemoglobin A/Hemoglobin.total in Blood by HPLC |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
42244-4 |
|
HPLC |
|
|
Observation |
|
|
|
0 |
Hgb A MFr Bld HPLC |
|
|
|
N |
|
Blood; Haemoglobin; Hb; HbA; HEMATOLOGY/CELL COUNTS; Hgb; Hgb A; High performance liquid chromatography; High pressure liquid chromatography; Mass Fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 42245-1 |
Hemoglobin A2/Hemoglobin.total |
MFr |
Bld |
Pt |
Qn |
HPLC |
|
ACTIVE |
Hemoglobin A2/Hemoglobin.total in Blood by HPLC |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
42245-1 |
|
HPLC |
|
|
Observation |
|
|
|
0 |
Hgb A2 MFr Bld HPLC |
|
|
|
N |
|
Blood; Haemoglobin; Hb; HEMATOLOGY/CELL COUNTS; Hgb; Hgb A2; High performance liquid chromatography; High pressure liquid chromatography; Mass Fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 42246-9 |
Hemoglobin F/Hemoglobin.total |
MFr |
Bld |
Pt |
Qn |
HPLC |
|
ACTIVE |
Hemoglobin F/Hemoglobin.total in Blood by HPLC |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
42246-9 |
|
HPLC |
|
|
Observation |
|
|
|
0 |
Hgb F MFr Bld HPLC |
|
|
|
N |
|
Blood; Fetal hemoglobin; Haemoglobin; Hb; HbF; HEMATOLOGY/CELL COUNTS; Hgb; Hgb F; High performance liquid chromatography; High pressure liquid chromatography; Mass Fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 42247-7 |
Hemoglobin pattern |
Imp |
Bld |
Pt |
Nar |
HPLC |
|
ACTIVE |
Hemoglobin pattern [Interpretation] in Blood by HPLC Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
42247-7 |
|
HPLC |
|
|
Observation |
|
|
|
0 |
Hgb Fract Bld HPLC-Imp |
|
|
|
N |
|
Blood; Haemoglobin; Hb; HEMATOLOGY/CELL COUNTS; Hgb; Hgb Fract; High performance liquid chromatography; High pressure liquid chromatography; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Narrative; Point in time; Random; Report; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 42248-5 |
Hemoglobin.other/Hemoglobin.total |
MFr |
Bld |
Pt |
Qn |
HPLC |
|
ACTIVE |
Hemoglobin.other/Hemoglobin.total in Blood by HPLC |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
42248-5 |
|
HPLC |
|
|
Observation |
|
|
|
0 |
Hgb Other MFr Bld HPLC |
|
|
|
N |
|
Blood; Haemoglobin; Hb; HEMATOLOGY/CELL COUNTS; Hgb; Hgb Other; High performance liquid chromatography; High pressure liquid chromatography; Mass Fraction; Othr; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 42249-3 |
levETIRAcetam |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
levETIRAcetam [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
42249-3 |
|
Screen |
|
|
Both |
|
|
|
0 |
levETIRAcetam Ur Ql Scn |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Keppra; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4225-9 |
Phenytoin |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Phenytoin [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4225-9 |
|
|
|
|
Observation |
|
|
|
0 |
Phenytoin Dose |
|
|
|
Y |
|
DI-HYDAN; Dilantin; Dilj; Diphenylhydantoin; Dose med or substance; DPH; DRUG DOSES; Epanutin; Fenantoin; Lehydan; Phenhydan; PHYT; Point in time; QNT; Quan; Quant; Quantitative; Random; Sinergina; Zentropil |
2.73 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 42250-1 |
Lymphocytes.variant/Leukocytes |
NFr |
Bld |
Pt |
Qn |
Automated count |
|
ACTIVE |
Variant lymphocytes/Leukocytes in Blood by Automated count |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
42250-1 |
|
Automated count |
|
|
Observation |
|
|
|
0 |
Variant Lymphs NFr Bld Auto |
|
|
|
N |
|
Atypical lymphocytes; Auto; Automated detection; Blood; Elec; Elect; Electr; HEMATOLOGY/CELL COUNTS; Leuc; Leuk; Leukocyte; Lkcs; Lymp; Lymph; Lympho; Lymphocyte; Lymphs; Lymphs%; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Reactive lymphocytes; Variant lymphocytes; Variant Lymphs; WB; WBC; WBCs; White blood cell; White blood cells; Whole blood |
2.79 |
2.16 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 42251-9 |
Methadone+Metabolite |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Methadone+Metabolite [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
42251-9 |
|
Screen |
|
|
Both |
|
|
|
0 |
Methadone+metab Ur Ql Scn |
|
|
|
N |
|
Addiction; Dolophin; Dolophine; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Metab; Metabolites; Metb; METD; Methadose; MTD; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42252-7 |
Methaqualone+Metabolite |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Methaqualone+Metabolite [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
42252-7 |
|
Screen |
|
|
Both |
|
|
|
0 |
Methaqualone+metab Ur Ql Scn |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Metab; Metabolites; Metb; Methaqualon; Methaqualone Metab; Ordinal; Point in time; PR; QL; Quaalude; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42253-5 |
Methylenedioxyamphetamine |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Methylenedioxyamphetamine [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
42253-5 |
|
|
|
|
Both |
|
|
|
0 |
MDA Ur Ql |
|
|
|
N |
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; MDA; Methylenedioxymethamphetamine metabolite; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42254-3 |
Nuclear Ab |
PrThr |
Ser |
Pt |
Ord |
IF |
|
ACTIVE |
Nuclear Ab [Presence] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
42254-3 |
|
IF |
|
|
Both |
|
|
|
0 |
ANA Ser Ql IF |
|
|
|
N |
|
ABS; Aby; ACIF; ANA; ANF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Antinuclear antibody; Autoantibodies; Autoantibody; FA; FANA; Fluorescent antibody; Fluoresent; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; NA; Nuc; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR; Time Resolved Fluorescence; TRF |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42255-0 |
Salmonella & Shigella sp |
Prid |
XXX |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Salmonella and Shigella sp identified in Specimen by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42255-0 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Salm + Shig Spec Cult |
|
|
|
N |
|
C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Nominal; Other; Point in time; Random; Sal; Salm + Shig; Salmonel; Shigellosis; Spec; species; spp; To be specified in another part of the message; Unspecified |
2.79 |
2.16 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; Previous Releases: Corrected Component from "Salmonella sp &or Shigella sp identified" because this term is nominal and should be used for assays that can identify and differentiate between Salmonella and Shigella. |
0 |
| 42256-8 |
Shigella boydii Ag |
PrThr |
Isolate |
Pt |
Ord |
|
|
ACTIVE |
Shigella boydii Ag [Presence] in Isolate |
|
MIN |
DefinitionDescription |
|
|
|
Positive/Negative |
|
|
|
|
|
MICRO |
|
42256-8 |
|
|
|
|
Both |
|
|
|
0 |
S boydii Ag Islt Ql |
|
|
|
N |
|
Antigen; Antigens; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; S boydii; Screen; Shigellosis |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
Changed answer list from "Normative" to "Example" to fit the current LOINC model.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42257-6 |
Shigella dysenteriae Ag |
PrThr |
Isolate |
Pt |
Ord |
|
|
ACTIVE |
Shigella dysenteriae Ag [Presence] in Isolate |
|
MIN |
DefinitionDescription |
|
|
|
Postive, Negative |
|
|
|
|
|
MICRO |
|
42257-6 |
|
|
|
|
Both |
|
|
|
0 |
S dysenter Ag Islt Ql |
|
|
|
N |
|
Antigen; Antigens; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; S dysenter; S dysenteriae; Screen; Shigellosis |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
Changed answer list from "Normative" to "Example" to fit the current LOINC model.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42258-4 |
Shigella flexneri Ag |
PrThr |
Isolate |
Pt |
Ord |
|
|
ACTIVE |
Shigella flexneri Ag [Presence] in Isolate |
|
MIN |
DefinitionDescription |
|
|
|
Positive, Negative |
|
|
|
|
|
MICRO |
|
42258-4 |
|
|
|
|
Both |
|
|
|
0 |
S flexneri Ag Islt Ql |
|
|
|
N |
|
Antigen; Antigens; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; S flexneri; Screen; Shigellosis |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
Changed answer list from "Normative" to "Example" to fit the current LOINC model.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42259-2 |
Shigella sonnei Ag |
PrThr |
Isolate |
Pt |
Ord |
|
|
ACTIVE |
Shigella sonnei Ag [Presence] in Isolate |
|
MIN |
DefinitionDescription |
|
|
|
Positive, Negative |
|
|
|
|
|
MICRO |
|
42259-2 |
|
|
|
|
Both |
|
|
|
0 |
S sonnei Ag Islt Ql |
|
|
|
N |
|
Antigen; Antigens; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; S sonnei; Screen; Shigellosis |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
Changed answer list from "Normative" to "Example" to fit the current LOINC model.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4226-7 |
Diphenylhydramine |
Mass |
Dose |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated diphenhydrAMINE [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4226-7 |
|
|
|
|
|
|
|
|
0 |
Deprecated Diphenylhydramine Dose |
|
|
|
|
|
Dose med or substance; DRUG DOSES; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 42260-0 |
Guidance for percutaneous biopsy^W contrast IV |
Find |
XXX |
Pt |
Doc |
CT |
|
ACTIVE |
CT Guidance for biopsy of Unspecified body region-- W contrast IV |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
42260-0 |
|
CT |
|
|
Both |
|
|
|
0 |
CT Guided Bx--W contr IV |
|
|
|
N |
|
Bx; c; CAT scan; Computed tomography; Computerized tomography; Contr; Contra; Contrst; CT scan; Document; Finding; Findings; Guid; Guide; Guided; Imaging; Misc; Miscellaneous; Other; Perc; Point in time; Rad; RADIOLOGY; Random; Spec; To be specified in another part of the message; Unspecified; W contr IV; WC |
2.64 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.;Updated the Component to include "percutaneous" to clarify the approach and make it explicit rather than assuming its presence. |
0 |
| 42261-8 |
Views for blood flow^W radionuclide IV |
Find |
Abdomen>Kidney |
Pt |
Doc |
NM |
|
ACTIVE |
NM Kidney Views for blood flow |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
42261-8 |
|
NM |
|
|
Both |
|
|
|
0 |
NM Kidney Vs bld flow W RNC IV |
|
|
|
N |
|
Abd; Abdo; Abdomen+; Abdominal; Bld flow; Document; Dynamic; Films; Finding; Findings; Imaging; Kidney; Nephric; Nephrology; Point in time; Rad; Radiology; Random; Renal; Renal function; Renogram; RN; RNC; Scan; View; Vs bld flow; VWS; W RNC IV |
2.64 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.;Changed System from "Kidney.bilateral" to "Abdomen>Kidney" for conformance with the LOINC/Radlex unified model. Removed "bilateral" from the System because, under normal circumstances, nuclear medicine kidney studies are always done on both kidneys (i.e., "bilateral" is implied) so including "bilateral" in the LOINC term is unnecessarily overspecifying the System. The meaning of the term has not changed.; Method of "Radnuc" was changed to "NM". The LOINC/RadLex Committee agreed to use a subset of the two-letter DICOM modality codes as the primary modality identifier. Changed Component from "Views flow" to "Views for blood flow" to clarify that assessing blood flow is the reason for exam; |
0 |
| 42262-6 |
Views for blood flow^W radionuclide IV |
Find |
Abdomen>Liver |
Pt |
Doc |
NM |
|
ACTIVE |
NM Liver Views for blood flow |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
42262-6 |
|
NM |
|
|
Both |
|
|
|
0 |
NM Liver Vs bld flow W RNC IV |
|
|
|
N |
|
Abd; Abdo; Abdomen+; Abdominal; Bld flow; Document; Dynamic; Films; Finding; Findings; Hepar; Hepatic; Imaging; Point in time; Rad; RADIOLOGY; Random; RN; RNC; Scan; View; Vs bld flow; VWS; W RNC IV |
2.64 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model. Changed Component from "Views flow" to "Views for blood flow" and System from "Liver" to "Abdomen>Liver" to conform with the RadLex/LOINC unified model and to clarify that assessing blood flow is the reason for exam; Method of "Radnuc" was changed to "NM". The LOINC/RadLex Committee agreed to use a subset of the two-letter DICOM modality codes as the primary modality identifier. |
0 |
